Morimoto M, Shimakawa S, Hashimoto T, Kitaoka T, Kyotani S
Japanese Red Cross Tokushima Hinomine Rehabilitation Center for People with Disabilities, Tokushima, Japan.
Graduate School of Pharmaceutical Sciences, Tokushima Bunri University, Tokushima, Japan.
J Clin Pharm Ther. 2018 Aug;43(4):571-573. doi: 10.1111/jcpt.12659. Epub 2017 Dec 18.
Dravet syndrome (DS) is an intractable epilepsy syndrome. The three-drug combination therapy of sodium valproate (VPA), clobazam (CLB) and stiripentol (STP) is recommended worldwide.
We present a case of DS, in which treatment with CLB could not be continued because of the appearance of adverse reactions to it. Replacement with topiramate (TPM) proved to be markedly effective.
It is suggested that combination therapy with VPA, TPM and STP is for DS epilepsy.
德雷维特综合征（DS）是一种难治性癫痫综合征。丙戊酸钠（VPA）、氯巴占（CLB）和司替戊醇（STP）的三联药物疗法在全球范围内被推荐。
我们报告一例DS病例，该病例因出现氯巴占不良反应而无法继续使用该药治疗。事实证明，改用托吡酯（TPM）治疗效果显著。
建议采用VPA、TPM和STP联合治疗DS癫痫。
